INVEST IN MED-X
All-Natural Pest Control Is Headed to the Nasdaq
The biopesticide market is expected to grow nearly 3X by 20301 while public health departments and big agriculture scramble to find safer pesticide options that don’t cause health problems or destroy the environment. Our natural, safe solutions have already produced sales up 200%, now expanding to 41 new markets. Invest as we approach our planned Nasdaq listing.
HIGHLIGHTS
Top 3 Reasons to Invest in Med-X
1. Rapid
Growth
200%
revenue growth in 5 years, from $647K in 2018 to $1.89M in 2023.
2. World-Class Partners
.png)
3. Nasdaq Here We Come
Meet MXRX
We’re planning a direct listing on the Nasdaq, and we’ve already reserved the ticker symbol "MXRX.” This is a rare opportunity to invest before it happens.
Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.
PROBLEM
Long-term Pesticide Exposure Linked to Human Diseases2
The negative effects caused by widespread pesticide use can be more dangerous as the pests themselves. The world is demanding a change. People and farmers desperately need safer, effective, alternative solutions to preserve food supplies and protect public health from pests but without the risks.
SOLUTION
Simpler, Safer, More Effective Pesticides
More than addressing just one issue with a “green” product, we’ve developed and refined a portfolio of proprietary plant-based products. Third-party studies prove our flagship Nature-Cide pesticides outperform chemical-based products.
Proven Effectiveness
Third-Party Independent Study proves Nature-Cide outperforms traditional synthetic vector control products using only essential oils from Clove, Cottonseed, Cedar, and Cinnamon.
No Chemicals
Our solutions are safe around children, pets, and the environment.
Complete Solution
One product line manages multiple pests in all settings. Less need to carry dozens of products for an operator. Same cost to use all-natural solutions.
200% Revenue Growth In 5 Years
The market wants our green solutions. We’ve consistently grown revenue year-over-year, from $647K in 2018 to $1.89M in 2023, 200% in total3. And we continue to form strategic partnerships across the value chain, including collaborations with key wholesale distributors.
Our Global Vision Is a $17.6B Opportunity
We’ve secured an exclusive agreements with Target Specialty Products, Ensystex and Preserve to introduce the Nature-Cide product line into 41 new markets, including but not limited to:
- Australia
- New Zealand
- Southeast Asia
- Caribbean Islands
- Africa
- Mexico
- And more
The global biopesticide market is expected to grow ~3X by 2030, from $5.8 billion in 2022 to an impressive $17.6 billion by 20301. We expect pesticide bans and other regulatory actions around the world to fuel our vision of Nature-Cide as the world’s leading “clean” pest control product.
- Direct Listing to the Nasdaq
- Export to Mexico, Central America, and the Caribbean.
- Acquire multiple profitable Nature-Cide product suppliers.
- Export to all of Southeast Asia and the Pacific Islands.
- Acquire like-minded businesses in the wellness and pest control industries that have similar distribution relationships as us.
- Export to Australia, New Zealand, South Africa, Canada, Middle East, and Africa.
- Start the Registration process in the EU.
- Expand the service division through M&A and become a “Top 100 Pest Control Company” in the US.
Our Roadmap for Growth
Once we list and get access to growth capital, management plans to launch its M&A strategy to bolster capitalization after the public market listing process4.
Get our investor deck for an in-depth look at our potential in the $17.6B global biopesticide market.
Watch Our Investor Q&A
Watch our most recent replay to gain valuable insights into our company and this exciting investment opportunity. This is a fantastic chance to learn directly from our leadership team and understand our vision and strategy. Stay tuned for future webinars where you can participate in live Q&A sessions and get your questions answered in real time.
Stay tuned about future webinars
Experienced Leadership Team
Operations Professional, Oversaw over $200M Revenue Book in Prior Role.
Clinical Investigator for Big Pharma and Family Physician for more than 24 years.
Finance Professional with Over 35 Years of Public Company Experience.
E-Commerce Professional with Significant Experience Scaling Companies.
Project Management and Human
Resources Professional.
Internal and Osteopathic Medicine.
Neurologist and Scientist.
Financial and Investment
Banking Specialist
Scientist and Mathematician.
FAQs
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Individuals over 18 years of age can invest.
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
The Common Stock (the "Shares") of Med-X (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.
In the event of death, divorce, or similar circumstance, shares can be transferred to:
• The company that issued the securities
• An accredited investor
• A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: investorrelations@medx-rx.com
At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
Join the Discussion